Preliminary data from the trial showed that TNX-102 SL did not achieve the primary goal of reducing pain in fibromyalgia patients by at least 30 percent over a three-month period.
Since the drug demonstrated a stronger effect on PTSD patients, the company will now shift their full attention to a late-stage study for this indication.
“We decided that PTSD was the better choice for us,” Seth Lederman, CEO of Tonix, told Reuters. He believes the treatment has potential to achieve a breakthrough therapy status as the Food and Drug Administration has not approved a new PTSD treatment in 15 years.
The company plans to conduct a late-stage study on TNX-102 SL’s ability to treat PTSD in the first quarter of 2017.
More articles on supply chain:
Study prompts formal recommendations for insulin injections
Merck halts development of osteoporosis drug in light of stroke risk
Clinton’s plan to address price hikes on long-standing drugs: 4 points
